# DESCRIPTION

## FIELD OF THE INVENTION

- introduce peptides and derivatives for treating T-cell mediated diseases

## BACKGROUND OF THE INVENTION

- describe HIV infection and immune response
- explain gp41 protein structure and function
- discuss prior art on gp41-derived peptides
- summarize T cell regulation and autoimmune diseases
- describe monocytes and macrophages in immune response
- highlight need for new treatments for inflammatory and autoimmune diseases

## SUMMARY OF THE INVENTION

- introduce peptides derived from HIV gp41 transmembrane domain
- describe therapeutic anti-inflammatory properties
- motivate co-localization with CD3/TCR complex
- summarize inhibition of T-cell proliferation
- describe inhibition of TNF-α secretion from macrophage
- introduce isolated peptides of 9-30 amino acids
- describe analogs and derivatives of isolated peptides
- introduce lipophilic conjugates of isolated peptides
- describe pharmaceutical compositions comprising isolated peptides
- outline methods of treating inflammatory diseases or disorders

## DETAILED DESCRIPTION OF THE INVENTION

- introduce peptides derived from HIV gp41 transmembrane domain
- describe immunosuppressive activity of peptides
- provide general formula for peptides and their analogs
- describe modifications and derivatives of peptides

### 1) Alanine (A), Serine (S), Threonine (T);

- define conservative substitutions

### 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

- define conservative substitutions
- describe peptide analogs with conservative substitutions
- describe peptide derivatives with chemical modifications
- describe peptide derivatives with side chain bond modifications
- describe peptide derivatives with backbone modifications
- describe diastereomeric peptides

### Hydrophobic Moieties

- define hydrophobic moiety
- describe examples of hydrophobic moieties
- detail coupling of hydrophobic moiety to peptide
- specify aliphatic groups
- list fatty acids as hydrophobic moieties

### Polynucleotide

- define polynucleotide
- describe isolated polynucleotide sequence
- detail expression vector
- outline methods for introducing vector into cells

### Pharmaceutical Compositions

- define pharmaceutical composition
- describe active ingredient
- describe lipopeptide embodiment
- describe pharmaceutically acceptable salts
- describe carriers and excipients
- describe formulation options
- describe dosage determination
- describe administration routes
- describe controlled release systems
- describe use of peptides in treating inflammatory diseases

## EXAMPLES

- peptide synthesis and fluorescent labeling
- FRET measurements
- co-localization of peptides with TCR molecules
- T-cell activation and proliferation

### Bioinformatics Database Analysis

- analyze TCRα CP-like transmembrane domain in viruses

### Example 2

- analyze distribution of gp41 TMD in resting and activated T cells

### Example 3

- examine effect of gp41 TMD peptide on T-cell proliferation in vitro

### Example 4

- examine effect of gp41 TMD peptide on T-cell activation induced by antibodies to CD3

### Example 5

- examine effect of gp41 TMD peptide on T-cell activation induced by PMA/ionomycin

### Example 6

- measure FRET between gp41 TMD and TCRα CP peptides

### Example 7

- measure FRET between gp41 TMD and TLR2 peptides

### Example 8

- examine effect of gp41 TMD peptide on TNFα secretion from RAW 264.7

